Biolegend, 138407, PE anti-mouse/human KLRG1 (MAFA) Antibody, 25μg

Killer cell lectin-like receptor G1 (KLRG1) is the mouse homolog of the rat mast cell function-associated antigen (MAFA or 2F1-Ag).  KLRG1 is a type II membrane glycoprotein that was first identified on the surface of rat mast cell line RBL-2H3.  It is composed of a homodimer of glycosylated 30-38 kD subunits.  Mouse and human homologs of KLRG1 are expressed by subsets of NK cells and lymphokine-activated killer (LAK) cells but not mast cells.  KLRG1 is also expressed on subsets of CD8 + and CD4 + cells, including CD4 + and CD8 + effector/memory cells, potent regulatory CD4 + T cells.  KLRG1 may be involved in regulating NK cell homeostasis.  KLRG1 was found to recognize cadherins and thus inhibit immune responses by regulating the effector function and the developmental processes of NK and T cells.
25μg
Verified Reactivity: Mouse, Human
Antibody Type: Monoclonal
Host Species: Syrian Hamster
Immunogen: IL-2 activated NK cells from C57BL/6 mice
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions.
Concentration: 0.2 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser: Blue Laser (488 nm)Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes: For successful staining of human cells, brighter fluorophore-antibody conjugates, such as PE, BV421™, or APC, are recommended.Additional reported applications (for relevant formats) include: Western Blotting1.
Application References(PubMed link indicates BioLegend citation): Robbins SH, et al. 2002. J. Immunol. 168:2585. (WB) Robbins SH, et al. 2003. J. Immunol. 170:5876. (FC) McMahon CW, et al. 2002. J. Immunol. 169:1444. (FC)
Product Citations: Moderzynski K, et al. 2016. PLoS Negl Trop Dis. . PubMed Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed Dalmas E et al. 2017. Immunity. 47(5):928-942 . PubMed Wang X, et al. 2023. Nat Commun. 14:3440. PubMed Heindl S, et al. 2021. J Exp Med. 218:. PubMed Liu C, et al. 2022. Regen Ther. 21:192. PubMed Alam A, et al. 2022. Cancer Cell. 40:153. PubMed Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed Burrack AL, et al. 2019. Cell Rep. 28:2140. PubMed Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed Potluri HK, et al. 2022. J Immunother Cancer. 10:. PubMed Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed Parriott G, et al. 2020. Immunology. 160:280. PubMed Zhang Y, et al. 2014. Infect Immun . 82:3033. PubMed Emgård J, et al. 2018. Immunity. 143:419. PubMed Shimokawa C et al. 2017. Immunity. 46(5):863-874 . PubMed Qi X, et al. 2019. Nat Med. 25:1225. PubMed Chun E, et al. 2020. Immunity. 51(5):871-884.e6.. PubMed Zhao H, et al. 2021. Int J Nanomedicine. 16:4913. PubMed McFarland AP, et al. 2021. Immunity. 54(6):1320-1337.e4. PubMed Toshiro Hirai et al. 2019. Immunity. 50(5):1249-1261 . PubMed Araujo Furlan CL, et al. 2018. Front Immunol. 2.149305556. PubMed Bal S, et al. 2016. Nat Immunol. 10.1038/ni.3444. PubMed Satoh–Takayama N, et al. 2020. Immunity. 52(4):635-649. PubMed Schultheiß C, et al. 2020. Immunity. 53(2):442-455.e4.. PubMed Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed Peng V, et al. 2022. Nat Immunol. 23:619. PubMed Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
RRID: AB_10574005 (BioLegend Cat. No. 138407) AB_10574313 (BioLegend Cat. No. 138408)
Disclaimer: This product may be used for research purposes only. It is not licensed for resale and may only be used by the buyer. This product may not be used and is not licensed for clinical assays, where the results of such assays are provided as a diagnostic service. If a diagnostic or therapeutic use is anticipated, then a license must be requested from the University of California. The availability of such diagnostic and therapeutic use license(s) cannot be guaranteed from the University of California.
Structure: KLRG1 is an inhibitory lectin-like type II transmembrane receptor containing a cytoplasmic motif similar to ITIM, expressed mainly as a homodimeric molecule consisting of two N-glycosylated subunits of approximately 30-38 kD.
Distribution: Subsets of NK cells, lymphokine-activated killer (LAK) cells and subsets of CD8+ and CD4+ cells.
Function: Regulates NK cell proliferation, maturation, and homeostasis. Inhibits immune responses by regulating the effector function and the developmental processes of NK and T cells.
Ligand/Receptor: E-cadherin
Cell Type: NK cells, T cells, Tregs
Biology Area: Immunology, Innate Immunity
Antigen References: 1. Grundemann C, et al. 2006. J. Immunol. 176:1311. 2. Blaser C, et al. 1998. J. Immunol. 161:6451. 3. Huntington ND, et al. 2007. J. Immunol. 178:4764. 4. Voehringer D, et al. 2001. J. Immunol. 167:4834.
Gene ID: 50928
UniProt: View information about KLRG1 on UniProt.org
Clone: 2F1/KLRG1
Regulatory Status: RUO
Other Names: MAFA, 2F1-Ag
Isotype: Syrian Hamster IgG
Q: What type of PE do you use in your conjugates?
A: We use R-PE in our conjugates.